We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+6.31%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$852M
AUM Growth
+$151M
Cap. Flow
+$67.7M
Cap. Flow %
7.95%
Top 10 Hldgs %
46.73%
Holding
164
New
33
Increased
26
Reduced
31
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$28.9M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.6M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.62M
4
FOLD
Amicus Therapeutics
FOLD
+$9.34M
5
PRTA icon
Prothena Corp
PRTA
+$7.38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$18.6M
2
BIIB icon
Biogen
BIIB
+$9.88M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.27M
4
ORBK
Orbotech Ltd
ORBK
+$6.41M
5
ZGNX
Zogenix, Inc.
ZGNX
+$5.08M

Sector Composition

Rank Sector Weight
1 Healthcare 61.72%
2 Miscellaneous 27.38%
3 Communication Services 3.9%
4 Technology 3.62%
5 Financials 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORLY icon
76
O'Reilly Automotive
ORLY
$68.7B
$2.8M 0.33%
174,750
+149,250
+585% +$2.22M
EXPE icon
77
Expedia Group
EXPE
$34.2B
$2.75M 0.32%
+22,950
New +$2.98M
CRBP icon
78
Corbus Pharmaceuticals
CRBP
$140M
$2.66M 0.31%
+12,500
New +$2.68M
PHXM
79
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$2.64M 0.31%
+12,000
New +$2.83M
MGNX icon
80
MacroGenics
MGNX
$263M
$2.63M 0.31%
138,700
-70,000
-34% -$1.31M
CASC
81
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.52M 0.3%
681,210
– –
SMMT icon
82
Summit Therapeutics
SMMT
$14.1B
$2.35M 0.28%
212,018
– –
PANW icon
83
Palo Alto Networks
PANW
$307B
$2.33M 0.27%
96,330
-28,500
-23% -$693K
CRVS icon
84
Corvus Pharmaceuticals
CRVS
$1.06B
$2.29M 0.27%
221,430
– –
ARDX icon
85
Ardelyx
ARDX
$873M
$2.28M 0.27%
345,000
– –
CPRX
86
DELISTED
Catalyst Pharmaceutical
CPRX
$2.25M 0.26%
+576,825
New +$1.91M
TEVA icon
87
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
$2.25M 0.26%
118,750
-281,250
-70% -$4.23M
RNAC icon
88
Cartesian Therapeutics
RNAC
$238M
$2.24M 0.26%
7,618
– –
CTIC
89
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.23M 0.26%
833,633
– –
CBAY
90
DELISTED
Cymabay Therapeutics
CBAY
$2.21M 0.26%
+240,000
New +$2.05M
ORBK
91
DELISTED
Orbotech Ltd
ORBK
$2.19M 0.26%
43,488
-131,755
-75% -$6.41M
SNDX icon
92
Syndax Pharmaceuticals
SNDX
$1.58B
$2.18M 0.26%
248,472
– –
EOCN
93
Eocene Ltd. Ordinary Shares
EOCN
$3.72M
$2.16M 0.25%
+165
New +$1.95M
VTRS icon
94
CALL
Viatris
VTRS
$19.7B
$2.12M 0.25%
50,000
-100,000
-67% -$3.82M
AAP icon
95
CALL
Advance Auto Parts
AAP
$2.53B
$2.09M 0.25%
21,000
– –
SRRA
96
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.05M 0.24%
+13,750
New +$1.32M
CMCSA icon
97
Comcast
CMCSA
$81.3B
$1.88M 0.22%
46,905
-19,455
-29% -$731K
KALA icon
98
KALA BIO
KALA
$10.9M
$1.85M 0.22%
+40
New +$1.87M
OVID icon
99
Ovid Therapeutics
OVID
$527M
$1.78M 0.21%
180,674
-125,000
-41% -$1.15M
MA icon
100
Mastercard
MA
$496B
$1.74M 0.2%
11,525
– –
2 3
4
5 6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sphera Funds Management held 164 positions worth $852M, up 22% from $701M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $67.7M of net new capital in Q4 2017, opening 33 new positions and adding to 26 existing holdings. Its largest new stake was Viatris: 756,449 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 65% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Biogen, an estimated $9.88M trimmed.

  • Sphera Funds Management's largest Q4 2017 buy was Viatris: 756,449 shares worth $32M.
  • Sphera Funds Management added most to Vertex Pharmaceuticals in Q4 2017, an estimated $9.62M increase.
  • Sphera Funds Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $9.88M.
  • Sphera Funds Management fully exited Gilead Sciences in Q4 2017, selling an estimated $18.6M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $852M portfolio in Q4 2017.
  • Sphera Funds Management opened 33 new positions and closed 28 in Q4 2017.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $852M.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.